Personalized strategies for brachytherapy of cervix cancer.

Autor: Camprodon G; Department of Radiation Oncology, hôpital Pitié Salpêtrière, Assistance publique-hôpitaux de Paris, Sorbonne université, Paris, France., Gabro A; Department of Radiation Oncology, hôpital Pitié Salpêtrière, Assistance publique-hôpitaux de Paris, Sorbonne université, Paris, France., El Ayachi Z; Department of Radiation Oncology, hôpital Pitié Salpêtrière, Assistance publique-hôpitaux de Paris, Sorbonne université, Paris, France., Chopra S; Department of Radiation Oncology and Medical Physics, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Nout R; Department of Radiation Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands., Maingon P; Department of Radiation Oncology, hôpital Pitié Salpêtrière, Assistance publique-hôpitaux de Paris, Sorbonne université, Paris, France., Chargari C; Department of Radiation Oncology, hôpital Pitié Salpêtrière, Assistance publique-hôpitaux de Paris, Sorbonne université, Paris, France. Electronic address: cyrus.chargari@aphp.fr.
Jazyk: angličtina
Zdroj: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2024 Nov; Vol. 28 (6-7), pp. 610-617. Date of Electronic Publication: 2024 Oct 11.
DOI: 10.1016/j.canrad.2024.09.006
Abstrakt: Among most tailored approaches in radiation oncology, the development of brachytherapy for the treatment of cervical cancer patients has benefited from various technological innovations. The development of 3D image-guided treatments was the first step for treatment personalization. This breakthrough preceded practice homogenization and validation of predictive dose and volume parameters and prognostic factors. We review some of the most significant strategies that emerged from the ongoing research in order to increase personalization in uterovaginal brachytherapy. A better stratification based on patients and tumors characteristics may lead to better discriminate candidates for intensification or de-escalation strategies, in order to still improve patient outcome while minimizing the risk of treatment-related side effects.
(Copyright © 2024 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: